Similar articles

• Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.

  Rothlisberger JM, Ovbiagele B. Rothlisberger JM, et al. J Comp Eff Res. 2015 Aug;4(4):377-84. doi: 10.2217/cer.15.22. J Comp Eff Res. 2015. PMID: 26274799 Free PMC article. Review.
• Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.

  Redman AR, Ryan GJ. Redman AR, et al. Expert Opin Pharmacother. 2004 Jan;5(1):117-23. doi: 10.1517/14656566.5.1.117. Expert Opin Pharmacother. 2004. PMID: 14680441 Review.
• Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.

  Chambers M, Hutton J, Gladman J. Chambers M, et al. Pharmacoeconomics. 1999 Nov;16(5 Pt 2):577-93. doi: 10.2165/00019053-199916050-00013. Pharmacoeconomics. 1999. PMID: 10662482 Clinical Trial.
• Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.

  Shah H, Gondek K. Shah H, et al. Clin Ther. 2000 Mar;22(3):362-70; discussion 360-1. doi: 10.1016/S0149-2918(00)80041-7. Clin Ther. 2000. PMID: 10963290
• Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.

  Matchar DB, Samsa GP, Liu S. Matchar DB, et al. Value Health. 2005 Sep-Oct;8(5):572-80. doi: 10.1111/j.1524-4733.2005.00050.x. Value Health. 2005. PMID: 16176495